Glasgow Outcome Scale Assessment in Patients with Cerebral Toxoplasmosis

Brigitta Berlianty, Sofiati Dian, Ahmad Rizal Ganiem


Background: Cerebral toxoplasmosis is a Toxoplasma gondii infection affecting the brain. Assessment of the functional outcome after treatment is needed as an evaluation for therapeutic management. One of the instruments used is the Glasgow Outcome Scale (GOS). This study aimed to assess the functional outcome of cerebral toxoplasmosis patients using GOS.

Methods: A Cross-sectional descriptive study with total sampling method was conducted. Medical records were retrieved from patients with cerebral toxoplasmosis registered at the Department of Neurology, Dr. Hasan Sadikin General Hospital, Bandung during year 2017–2019. Inclusion criteria were patients with cerebral toxoplasmosis aged >18 years and had a positive HIV serological test. The GOS was assessed and presented in frequency, using Microsoft Excel and SPSS software ver. 25.0.

Results: Of 87 patients, 68% had somnolent on admission to the hospital, 51% had hemiparesis/hemiplegia, and 76% had GOS 3, indicating severe disability. Almost one third (28%) of patients died during hospitalization with non-neurological complications as the most common cause of death (63%). On discharge from the hospital, 82% of the survivors were fully alert, 40% had hemiparesis/hemiplegia, and 33% had GOS 4 (mild disability).

Conclusions: Most of the cerebral toxoplasmosis patients come to the hospital with severe disability. During the treatment, one third of patients died, and those who survived had mild disability. GOS has improved after hospitalization, suggesting that GOS is useful for assessment of therapeutic management.


Cerebral toxoplasmosis, Glasgow Outcome Scale, opportunistic infection, Toxoplasma gondii

Full Text:



Barman B, Tiewsoh I, Lynrah K, Wankhar B, Issar N. Cerebral toxoplasmosis with fever and erythematous macular rash: An initial presentation in an advanced HIV infection. Trop Parasitol. 2018;8(1):41–4.

Lee J, Ryu JS. Current status of parasite infections in Indonesia: a literature review. Korean J Parasitol. 2019;57(4):329–39.

Tuda J, Adiani S, Ichikawa-Seki M, Umeda K, Nishikawa Y. Seroprevalence of Toxoplasma gondii in humans and pigs in North Sulawesi, Indonesia. Parasitol Int. 2017;66(5):615–8.

Vidal JE. HIV-related cerebral toxoplasmosis revisited: current concepts and controversies of an old disease. J Int Assoc Provid AIDS Care. 2019;18:2325958219867315.

de Oliveira GB, da Silva MAL, Wanderley LB, da Cunha Correia C, Ferreira ECB, de Medeiros ZM, et al. Cerebral toxoplasmosis in patients with acquired immune deficiency syndrome in the neurological emergency department of a tertiary hospital. Clin Neurol Neurosurg. 2016;150:23–6.

Pustorino G, Ferlazzo E, Carpentieri MS, Cianci V, Gasparini S, Campello M, et al. Cerebral toxoplasmosis diagnosed by brain tissue PCR analysis in an immunocompetent patient. Neurol Clin Pract. 2017;7(5):436–8.

Flegr J, Prandota J, Sovičková M, Israili ZH. Toxoplasmosis-a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS One. 2014;9(3):e90203.

Elsheikha HM, Marra CM, Zhu XQ. Epidemiology, pathophysiology, diagnosis, and management of cerebral toxoplasmosis. Clin Microbiol Rev. 2020;34(1):e00115–9.

Yostila D, Armen A. Toxoplasmosis cerebri pada HIV AIDS. Jurnal Kesehatan Andalas. 2018;7(Supplement 4):96–9.

Schlüter D, Barragan A. Advances and challenges in understanding cerebral toxoplasmosis. Front Immunol. 2019;10:242.

Wilson L, Boase K, Nelson LD, Temkin NR, Giacino JT, Markowitz AJ, et al. A manual for the Glasgow Outcome Scale-extended interview. J Neurotrauma. 2021;38(17):2435–46.

Weir J, Steyerberg EW, Butcher I, Lu J, Lingsma HF, McHugh GS, et al. Does the extended Glasgow outcome scale add value to the conventional Glasgow outcome scale? J Neurotrauma. 2012;29(1):53–8.

McMillan T, Wilson L, Ponsford J, Levin H, Teasdale G, Bond M. The Glasgow Outcome Scale-40 years of application and refinement. Nat Rev Neurol. 2016;12(8):477–85.

Fuller GW, Hernandez M, Pallot D, Lecky F, Stevenson M, Gabbe B. Health state preference weights for the Glasgow Outcome Scale following traumatic brain injury : a systematic review and mapping study. Value Health. 2016;20(1):141–51.

Wang ZD, Wang SC, Liu HH, Ma HY, Li ZY, Wei F, et al. Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: a systematic review and meta-analysis. Lancet HIV. 2017;4(4):e177–88.

Sonneville R, Schmidt M, Messika J, Hssain AA, da Silva D, Klein IF, et al. Neurologic outcomes and adjunctive steroids in HIV patients with severe cerebral toxoplasmosis. Neurology. 2012;79(17):1762–6.

Indrayani I. Uji validitas kadar CD4 untuk diagnosis toksoplasmosis serebri pada penderita acquired immuno deficiency syndrome [thesis]. Denpasar: Universitas Udayana; 2011.

Kodliwadmath HB, Koppad SN, Desai M, Badiger SP. Correlation of Glasgow outcome score to Glasgow coma score assessed at admission. Int Surg J. 2016:3(4):1959–63.

Indradmojo C, Zaiyanah M, Setijowati N, Eddy MI. Faktor-faktor yang mempengaruhi nilai Glasgow outcome scale pada pasien trauma kepala (Studi di IGD RSUD Dr. Iskak Tulungagung). Maj Kesehat. 2020;7(3):183–90.

Suwaryo PAW, Yuwono P. Penggunaan Glasgow Outcome Scale dalam penilaian kondisi pasien pasca cedera kepala. Jurnal Ilmiah Kesehatan Keperawatan. 2018;13(3):107–13.

Hassana DS, Hadisaputro S, Sofro MAU. Toxoplasmosis and cerebral toxoplasmosis in HIV/AIDS patients in Kariadi Hospital, Semarang. J Epid Kes Kom. 2021:6(1):213–7.

Azovtseva OV, Viktorova EA, Bakulina EG, Shelomov AS, Trofimova TN. Cerebral toxoplasmosis in HIV-infected patients over 2015–2018 (a case study of Russia). Epidemiol Infect. 2020;148:e142.

Mendez OA, Koshy AA. Toxoplasma gondii: Entry, association, and physiological influence on the central nervous system. PLoS Pathog. 2017;13(7):e1006351.

Wibawani R, Soeprijanto B, Ferriastuti W, Triono EA. Head computed tomography images of HIV/AIDS patients with suspected cerebral toxoplasmosis in Dr. Soetomo General Hospital Surabaya. Biomolecular Health Sci J. 2019;02(01):21–6.

Bondarenko AV, Katsapov DV, Gavrylov AV, Didova TV, Nahornyi IA. Immunodiagnostics of cerebral toxoplasmosis depending on permeability of blood-brain barrier. Wiad Lek. 2020;73(2):285–8.

Abbasi Fard S, Khajeh A, Khosravi A, et al. Fulminant and diffuse cerebral toxoplasmosis as the first manifestation of HIV infection: a case presentation and review of the literature. Am J Case Rep. 2020;21:e919624.

Ozaras R, Karaismailoglu B, Vatan A, Hasiloglu Z, Sahin S, Oz B. Cerebral toxoplasmosis. QJM. 2016;109(7):491–2.

Greenway MRF, Sacco KA, Burton MC. In deep: cerebral toxoplasmosis. Am J Med. 2017;130(7):802–4.

Patel J, Kuppachi S. AKI in a patient with cerebral toxoplasmosis. Kidney360. 2020;1(4):316–7.

Opintan JA, Awadzi BK, Biney IJK,Ganu V, Doe R, Kenu E, et al. High rates of cerebral toxoplasmosis in HIV patients presenting with meningitis in Accra, Ghana. Trans R Soc Trop Med Hyg. 2017;111(10):464–71


Article Metrics

Abstract view : 277 times
PDF - 207 times

 This Journal indexed by


Creative Commons License
AMJ is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License


View My Stats